<span item_type="fundamental" item_id="b3c123bea23fed13217e3b25a076eaaa" counter_id="ST/US/SLXNW" env="prod"></span><span item_type="announcement" item_id="515752481619252225" env="prod"></span><p>EPS: As of FY2025 Q1, the actual value is USD 0.26.</p><p></p><h3>Cash Position</h3><p>Cash and cash equivalents were $6.2 million as of March 31, 2025, compared to $1.2 million as of December 31, 2024. This increase was primarily due to successful financing activities during the quarter, partially offset by operating expenses supporting clinical and preclinical development.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891325001763/exihibt_99-1.htm"></span></p><h3>Operating Expenses</h3><p>Total operating expenses for Q1 2025 were $1.7 million, compared to $1.3 million in the same period of 2024. Research and development expenses decreased to $0.6 million for Q1 2025, compared to $1.0 million for Q1 2024, primarily due to decreased subcontractors and consultants expenses. General and administrative expenses increased to $1.1 million for Q1 2025, compared to $0.3 million for Q1 2024, mainly due to increased payroll expenses and higher professional services costs related to financing activities as a public company.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891325001763/exihibt_99-1.htm"></span></p><h3>Financial Expenses</h3><p>Financial expenses, net for Q1 2025 were $0.1 million, compared to $0.2 million in Q1 2024, mainly due to reduced foreign exchange losses.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891325001763/exihibt_99-1.htm"></span></p><h3>Net Loss</h3><p>Net loss for the first quarter of 2025 was $1.7 million, compared to $1.4 million for the first quarter of 2024. The increase was mainly due to higher general and administrative expenses related to being a public company, partially offset by decreased research and development expenses.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891325001763/exihibt_99-1.htm"></span></p><h3>Outlook / Guidance</h3><p>Silexion Therapeutics plans to advance its pipeline toward clinical development, leveraging its enhanced financial position and strategic collaborations. The company aims to initiate clinical trials for its expanded dual-route development strategy for SIL204 in the first half of 2026. Additionally, Silexion has entered a strategic collaboration with Catalent to conduct formulation development and clinical manufacturing activities for SIL204.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891325001763/exihibt_99-1.htm"></span></p>

SILEXION THERAPEUTICS CORP C/WTS EXP 15/08/2029 (TO PUR COM) | 8-K: FY2025 Q1 EPS: USD 0.26